Spondyloarthritis & psoriatic arthritis
Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study
Authors' conclusion
DFR is attainable in oligoarticular/polyarticular PsA and is sustainable in 9% of patients.
Study context
- Population
- Newly diagnosed patients with oligoarticular/polyarticular psoriatic arthritis (PsA) treated with disease-modifying antirheumatic drugs (DMARDs), Dutch southwest Early Psoriatic Arthritis cohort
- Participants
- 451 participants
- Outcome
- Prevalence of DMARD-free remission (DFR: no clinical synovitis ≥3 months after DMARD cessation) and sustained DFR (SDFR: >1 year)
Methodological detailslongitudinal
- Longitudinal
Main finding
As reported in the abstract
DFR, SDFR and true SDFR (prevalence) · median 5.1 years (IQR, 3.0-7.3 years)
- Reached drug-free remission (DFR)
- 22%
- Early flare after DFR
- 4.7%
- SDFR achieved
- 14.4%
- Late flare
- 5.3%
- True SDFR (SDFR without flaring)
- 9.1%
Observational data: associations, not effects.
Further findings
Time from DMARD cessation to late flare
- Median 1.7 years (IQR, 1.4-2.8 years)
Independent predictors of true SDFR
- Low baseline Disease Activity Index in Psoriatic Arthritis and never using b/tsDMARDs were independent predictors
HAQ at time of true SDFR
- Similar to general population; median 0.12 (IQR, 0-0.75)
Original publication
Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study. Ann Rheum Dis. Published 16 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →